You are here

  • Home
  • Archive
  • Volume 69, Issue 6
  • Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Article Text

Article menu

Download PDFPDF

XML
Helicobacter pylori
Original research
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
  1. Sho Suzuki1,2,
  2. Takuji Gotoda1,
  3. Chika Kusano1,
  4. Hisatomo Ikehara1,
  5. Ryoji Ichijima1,
  6. Motoki Ohyauchi3,
  7. Hirotaka Ito3,
  8. Masashi Kawamura4,
  9. Yohei Ogata4,
  10. Masahiko Ohtaka5,
  11. Moriyasu Nakahara6,
  12. Koichi Kawabe7
  1. 1 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
  2. 2 Department of Gastroenterology, Yuri Kumiai General Hospital, Yurihonjo, Akita, Japan
  3. 3 Department of Gastroenterology, Osaki Citizen Hospital, Osaki, Miyagi, Japan
  4. 4 Department of Gastroenterology, Sendai City Hospital, Sendai, Miyagi, Japan
  5. 5 Yamanashi Koseiren Health Care Center, Kofu, Yamanashi, Japan
  6. 6 Department of Gastroenterology, Chichibu Municipal Hospital, Chichibu, Saitama, Japan
  7. 7 Department of Gastroenterology, Fukaya Red Cross Hospital, Fukaya, Saitama, Japan
  1. Correspondence to Professor Takuji Gotoda, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo 101-8309, Japan; takujigotoda{at}yahoo.co.jp

Abstract

Objective To date, no randomised trials have compared the efficacy of vonoprazan and amoxicillin dual therapy with other standard regimens for Helicobacter pylori treatment. This study aimed to investigate the efficacy of the 7-day vonoprazan and low-dose amoxicillin dual therapy as a first-line H. pylori treatment, and compared this with vonoprazan-based triple therapy.

Design This prospective, randomised clinical trial was performed at seven Japanese institutions. Patients with H. pylori–positive culture test and naive to treatment were randomly assigned in a 1:1 ratio to either VA-dual therapy (vonoprazan 20 mg+amoxicillin 750 mg twice/day) or VAC-triple therapy (vonoprazan 20 mg+amoxicillin 750 mg+clarithromycin 200 mg twice/day) for 7 days, with stratification by age, sex, H. pylori antimicrobial resistance and institution. Eradication success was evaluated by 13C-urea breath test at least 4 weeks after treatment.

Results Between October 2018 and June 2019, 629 subjects were screened and 335 were randomised. The eradication rates of VA-dual and VAC-triple therapies were 84.5% and 89.2% (p=0.203) by intention-to-treat analysis, respectively, and 87.1% and 90.2% (p=0.372) by per-protocol analysis, respectively. VA-dual was non-inferior to VAC-triple in the per-protocol analysis. The eradication rates in strains resistant to clarithromycin for VA-dual were significantly higher than those for VAC-triple (92.3% vs 76.2%; p=0.048). The incidence of adverse events was equal between groups.

Conclusion The 7-day vonoprazan and low-dose amoxicillin dual therapy provided acceptable H. pylori eradication rates and a similar effect to vonoprazan-based triple therapy in regions with high clarithromycin resistance.

Trial registration number UMIN000034140.

  • helicobacter pylori - treatment
  • antibiotics - clinical trials
  • gastric inflammation
  • clinical trials
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/gutjnl-2019-319954

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @ShoSuzuki12

    • Contributors SS, TG and CK planned and designed the study. SS and TG wrote the manuscript. SS, RI, HirI, YO, MasO, MN and KK had leadership in each institution and collected data. HisI, MotO and MK made critical revision of the manuscript. All the authors approved the final manuscript.

    • Funding This study was founded by Nihon University School of Medicine.

    • Competing interests TG received honorarium from Takeda Pharmaceutical Company Limited, the manufacturer of study drugs.

    • Patient consent for publication Obtained.

    • Ethics approval The study protocol was approved by the institutional review board of each participating unit, and the protocol was not changed after the trial commenced.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data are available on reasonable request. De-identified data sets and protocol of the present study will be made available by reasonable request from the UMIN Individual Case Data Repository (https://www.umin.ac.jp/icdr/index.html).